MigraineMind research summary

Sustained response to atogepant in episodic and chronic migraine: Post-hoc analyses of ELEVATE and PROGRESS, and their open-label extension.

Cephalalgia | 2026

Clinical trial
AuthorsCho SJ, Friedman DI, Chalermpalanupap N, Nahas SJ, Dabruzzo B
JournalCephalalgia
Publication year2026
PubMed ID43042641

Summary

These analyses looked at how effective atogepant is for migraine treatment. Atogepant is a daily pill that blocks certain pain signals. Researchers studied data from two trials called ELEVATE and PROGRESS. They also examined data from a follow-up study. Participants had either episodic or chronic migraines. The goal was to see how many people had lasting relief from migraines. They measured this by tracking how many fewer migraine days participants had each month. Results showed that a significant number of patients experienced sustained improvement. This means they had fewer migraine days over time. The findings suggest that atogepant could be a helpful option for people struggling with migraines. It’s important to consider how well patients respond to this treatment long-term. Overall, atogepant shows promise in managing both episodic and chronic migraines effectively. Clinical relevance: Atogepant may provide lasting relief for patients with episodic or chronic migraines, improving their quality of life and reducing the frequency of migraine attacks.

Related migraine research topics

Original research

Read the original publication and review its full methods and findings on PubMed.

MigraineMind is an educational resource designed to complement—not replace—the original scientific literature or clinical judgement. This page is an AI-generated summary of the available paper information and may contain errors. Please consult the original publication.